Following after is AXS-12 (reboxetine) for narcolepsy, which could be filed in 2023. In addition to its pipeline candidates, Axsome also has US rights to Jazz Pharma's dual-acting dopamine and ...

The best endurance road bikes will help you go far and fast in comfort, thanks to specs, geometry and features that aren't as aggressive as a full-blown race bike. All-road bikes also fall under the ...

The FDA was supposed to be delivering its verdict on Axsome Therapeutics' depression therapy AXS-05 in less than a fortnight – but instead has delivered the company a letter outlining deficiencies in ...

Julia Kagan is a financial/consumer journalist and former senior editor, personal finance, of Investopedia. Chip Stapleton is a Series 7 and Series 66 license holder, CFA Level 1 exam holder, and ...